APG Asset Management N.V. Has $27.55 Million Holdings in ResMed Inc. (NYSE:RMD)

APG Asset Management N.V. raised its holdings in shares of ResMed Inc. (NYSE:RMD - Free Report) by 189.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 124,755 shares of the medical equipment provider's stock after purchasing an additional 81,643 shares during the period. APG Asset Management N.V. owned about 0.08% of ResMed worth $27,552,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Howard Capital Management Inc. raised its stake in ResMed by 5.3% during the fourth quarter. Howard Capital Management Inc. now owns 900 shares of the medical equipment provider's stock worth $206,000 after acquiring an additional 45 shares during the period. SkyView Investment Advisors LLC raised its position in shares of ResMed by 2.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 2,610 shares of the medical equipment provider's stock worth $637,000 after purchasing an additional 51 shares during the period. Wedmont Private Capital lifted its holdings in shares of ResMed by 2.6% in the 4th quarter. Wedmont Private Capital now owns 2,032 shares of the medical equipment provider's stock worth $475,000 after purchasing an additional 52 shares during the last quarter. HighPoint Advisor Group LLC boosted its position in ResMed by 2.6% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,570 shares of the medical equipment provider's stock valued at $610,000 after purchasing an additional 64 shares during the period. Finally, Brooklyn Investment Group grew its stake in ResMed by 8.1% during the 4th quarter. Brooklyn Investment Group now owns 911 shares of the medical equipment provider's stock worth $208,000 after buying an additional 68 shares during the last quarter. 54.98% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

RMD has been the subject of a number of recent analyst reports. Piper Sandler increased their price objective on ResMed from $252.00 to $260.00 and gave the stock a "neutral" rating in a report on Friday, January 31st. JPMorgan Chase & Co. upped their price objective on shares of ResMed from $270.00 to $286.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. StockNews.com cut shares of ResMed from a "buy" rating to a "hold" rating in a research note on Wednesday, April 2nd. Needham & Company LLC reaffirmed a "hold" rating on shares of ResMed in a research note on Friday, January 31st. Finally, Citigroup raised ResMed from a "neutral" rating to a "buy" rating in a report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $249.73.

Insider Activity

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the firm's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the sale, the director now directly owns 77,218 shares in the company, valued at approximately $18,695,249.98. This trade represents a 2.52 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Kaushik Ghoshal sold 9,745 shares of ResMed stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $239.31, for a total value of $2,332,075.95. Following the transaction, the insider now directly owns 9,725 shares in the company, valued at approximately $2,327,289.75. This trade represents a 50.05 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 49,013 shares of company stock worth $11,298,816. 0.71% of the stock is owned by corporate insiders.

ResMed Trading Down 1.0 %

RMD traded down $2.16 during trading on Tuesday, reaching $212.37. The company had a trading volume of 280,546 shares, compared to its average volume of 1,024,237. The firm's 50-day simple moving average is $225.09 and its 200 day simple moving average is $235.22. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The company has a market cap of $31.19 billion, a price-to-earnings ratio of 25.07, a PEG ratio of 1.53 and a beta of 0.75. ResMed Inc. has a 12-month low of $172.19 and a 12-month high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last released its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. Equities research analysts anticipate that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th were given a $0.53 dividend. The ex-dividend date of this dividend was Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 1.00%. ResMed's dividend payout ratio (DPR) is presently 25.03%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.